



Published in final edited form as:

J Mol Biol. 2015 November 20; 427(23): 3766–3784. doi:10.1016/j.jmb.2015.09.020.

Diversification of β -Augmentation Interactions between CDI Toxin/ Immunity Proteins

Robert P. Morse¹, Julia L.E. Willett², Parker M. Johnson¹, Mandy Zheng³, Alfredo Credali¹, Angelina Iniguez¹, James S. Nowick³, Christopher S. Hayes^{2,4}, and Celia W. Goulding^{1,5}

¹Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92697, USA

²Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA 93106-9625, USA

³Department of Chemistry, University of California, Irvine, Irvine, CA 92697, USA

⁴Biomolecular Science and Engineering Program, University of California, Santa Barbara, Santa Barbara, CA 93106-9625, USA

⁵Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA

Abstract

Contact-dependent growth inhibition (CDI) is a widespread mechanism of inter-bacterial competition mediated by the CdiB/CdiA family of two-partner secretion proteins. CdiA effectors carry diverse C-terminal toxin domains (CdiA-CT), which are delivered into neighboring target cells to inhibit growth. CDI⁺ bacteria also produce CdiI immunity proteins that bind specifically to cognate CdiA-CT toxins and protect the cell from auto-inhibition. Here, we compare the structures of homologous CdiA-CT/CdiI complexes from *Escherichia coli* EC869 and *Yersinia pseudotuberculosis* YPIII to explore the evolution of CDI toxin/immunity protein interactions. Both complexes share an unusual β -augmentation interaction, in which the toxin domain extends a β -hairpin into the immunity protein to complete a six-stranded anti-parallel sheet. However, the specific contacts differ substantially between the two complexes. The EC869 β -hairpin interacts mainly through direct H-bond and ion-pair interactions, whereas the YPIII β -hairpin pocket contains more hydrophobic contacts and a network of bridging water molecules. In accord with these differences, we find that each CdiI protein only protects target bacteria from its cognate CdiA-CT toxin. The compact β -hairpin binding pocket within the immunity protein represents a tractable system for the rationale design of small molecules to block CdiA-CT/ CdiI complex formation. We synthesized a macrocyclic peptide mimic of the β -hairpin from EC869 toxin and solved its structure in complex with cognate immunity protein. These latter studies suggest that small molecules could potentially be used to disrupt CDI toxin/immunity complexes.

Correspondence to Celia W. Goulding: Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA. celia.goulding@uci.edu.

Accession numbers

Coordinates and structure factors have been deposited in the Protein Data Bank with accession numbers 4ZQU, 4ZQV and 4ZQW.

Keywords

bacterial competition; interspecies growth inhibition; DNase; toxin/immunity proteins

Introduction

Bacteria possess many strategies to compete and cooperate with other microorganisms in the environment. Contact-dependent growth inhibition (CDI) is one competitive mechanism used by some Gram-negative species to inhibit the growth of neighboring bacteria [1,2]. CDI⁺ cells express CdiB/CdiA two-partner secretion systems, which deliver protein toxins into target bacteria through a receptor-mediated process. CdiB is an Omp85 outer-membrane protein that exports and assembles toxic CdiA effectors onto the surface of CDI⁺ cells. CdiA proteins range from 180 to 630 kDa depending on bacterial species and form β -helical filaments that are predicted to extend several hundred angstroms (Å) from the inhibitor-cell surface. CdiA binds to specific receptors on susceptible bacteria and subsequently delivers a toxin domain derived from its C-terminus (CdiA-CT) into the target cell [3–5]. CDI⁺ bacteria deploy a variety of CdiA-CT toxins with distinct activities. The CdiA-CT^{EC93} from *Escherichia coli* EC93 dissipates ion gradients by forming membrane pores [6], but most other characterized CDI toxins have specific nuclease activities. CDI toxins from *E. coli* EC869 and *Dickeya dadantii* 3937 are potent DNases capable of degrading target-cell chromosomes [5,7], and CdiA-CT^{ECL} from *Enterobacter cloacae* ATCC 13047 cleaves 16S rRNA to block protein synthesis [8]. CDI⁺ bacteria protect themselves from auto-inhibition by producing small CdiI immunity proteins that bind to the CdiA-CT and block its toxin activity. Because CDI toxins are diverse, CdiA-CT/CdiI protein interactions are necessarily specific between cognate pairs. Therefore, CdiI immunity proteins neutralize their cognate CdiA-CT but provide no protection against the toxins deployed by other bacteria [7,9]. This diverse network of toxin/immunity pairs suggests that CDI plays an important role in inter-cellular competition and self/non-self recognition.

We recently surveyed the UniProt database and identified at least 120 distinct CdiA-CT toxin families. Only 26 of these toxins have Pfam designations [10] and the remaining domains are uncharacterized. We initiated structural studies of these protein pairs to discover new toxin activities and toxin/immunity binding interactions. The first CDI toxin/immunity protein complex structures to be determined were from *Burkholderia pseudomallei* 1026b and enterohemorrhagic *E. coli* strain EC869 [7]. The CdiA-CT toxin sequences from these bacteria are not related, yet the three-dimensional structures of the domains superimpose with an rmsd of 3.9 Å. Structural homology searches revealed significant similarity to type IIS restriction endonucleases, suggesting that both toxins are DNases. Indeed, the C-terminal domain of CdiA-CT_{o11}^{EC869} has potent Zn²⁺-dependent DNase activity *in vitro* and *in vivo* [7]. However, CdiA-CT_{II}^{Bp1026b} has no detectable activity on DNA, and instead this toxin preferentially cleaves near the 3'-end of tRNA^{Ala} molecules [11]. Thus, the same toxin fold is used to target different nucleic acid substrates. Though CdiA-CT_{o11}^{EC869} and CdiA-CT_{II}^{Bp1026b} are similar in structure, other CDI toxins do not share the type IIS restriction endonuclease fold. The crystal structure of CdiA-CT^{ECL} from *E. cloacae* ATCC 13047 reveals similarity to the C-terminal nuclease domain

of colicin E3 [8,12,13], and sequence homology and activity studies strongly suggest that CdiA-CT^{K96243} from *B. pseudomallei* K96243 is related to the C-terminal nuclease domain of colicin E5 [2,11]. Moreover, Aravind and colleagues have predicted that CDI systems deploy two classes of RNA deaminase (Pfam: PF14424 and PF14437), as well as homologues of the EndoU poly(U)-specific endonuclease that processes eukaryotic snoRNAs (Pfam: PF14436) [10,14,15]. Thus, CDI represents a versatile platform to deliver structurally diverse toxins into Gram-negative bacteria.

Although toxin/immunity pairs within a given family are homologous, there is often considerable sequence diversity between members, suggesting that families continue to diverge and evolve. When viewed in the context of available crystal structures, it is apparent that residues at the interface of the toxin/immunity protein complexes are diversifying most rapidly. This phenomenon is exemplified by toxin/immunity proteins that are homologous to the orphan-11 (o11) CdiA-CT/CdiI pair from *E. coli* EC869 [7,9]. CdiA-CT_{o11}^{EC869} interacts with CdiI_{o11}^{EC869} through β -augmentation, in which the toxin domain extends a β -hairpin to complete a six-stranded anti-parallel β -sheet within the immunity protein (Fig. 1a) [7]. The sequences encoding the β -hairpin (corresponding to β 4 and β 5) are the most variable between members of the CdiA-CT_{o11}^{EC869} nuclease family (Fig. 1b). Moreover, CdiI_{o11}^{EC869} residues that interact with the toxin are not conserved between related immunity proteins (Fig. 1c), suggesting that each immunity protein is specific for its cognate toxin. Here, we use structure–function analyses to examine the β -augmentation interactions of two homologous CdiA-CT/CdiI complexes to study the diversification of CDI toxin/immunity protein interfaces. We find that the CdiA-CT/CdiI^{YP113} complex from *Yersinia pseudotuberculosis* YP113 also features a β -augmentation interaction; however, the precise intermolecular contacts differ substantially between the complexes. In accord with these differences, each CdiI immunity protein only protects against its cognate toxin, demonstrating that each pair is a distinct cognate toxin/immunity pair. Finally, we synthesized a macrocyclic peptide mimic of the β -hairpin from CdiA-CT_{o11}^{EC869} and solved its crystal structure in complex with the CdiI_{o11}^{EC869} immunity protein. This structure forms the basis to refine the β -hairpin mimic to increase affinity with the goal of producing compounds that activate DNase toxins through sequestration of immunity proteins.

Results

Structure of the CdiA-CT/CdiI^{YP113} complex reveals conservation of the β -augmentation interaction

Alignment of CdiA-CT_{o11}^{EC869} toxin homologues indicates that most secondary-structure elements have high level of sequence conservation with the exception of strands β 4 and β 5, which mediate the β -augmentation interaction with CdiI_{o11}^{EC869} (Fig. 1a and b). To determine whether β -augmentation occurs in other homologous toxin/immunity pairs, we performed structural and functional analyses of the CdiA-CT/CdiI^{YP113} complex encoded by the YPK_0575/YPK_0576 genes of *Y. pseudotuberculosis* YP113. The C-terminal nuclease domain of CdiA-CT^{YP113} is 70.4% identical with CdiA-CT_{o11}^{EC869} and shares all of the predicted active-site residues (Fig. 1b). Similarly, the CdiI^{YP113} and CdiI_{o11}^{EC869} immunity

proteins share 49.1% identity, though CdiI^{YPIII} contains a 10-residue insertion between $\alpha 1$ and $\alpha 2$ that is predicted to produce an elongated loop (Fig. 1c). We solved the crystal structure of the CdiA-CT/CdiI^{YPIII} complex to 2.1 Å resolution by molecular replacement using the structure of the CdiA-CT/CdiI_{o11}^{EC869} complex (PDB code: 4G6U) as a search model (Fig. 2a). As with other CdiA-CT domains [7,8], the N-terminal region (residues Val1–Gly173) was not resolved in the structure. The final model included CdiA-CT^{YPIII} residues 174–298 and 148 water molecules resulting in an $R_{\text{work}}/R_{\text{free}}$ (%) of 20.5/25.6 (Table 1). The CdiA-CT/CdiI_{o11}^{EC869} and CdiA-CT/CdiI^{YPIII} complexes have very similar structures. The toxin domains superimpose with rmsd of 0.84 Å over 101 of 123 α -carbons, and the immunity proteins superimpose with rmsd of 1.01 Å over 133 of 173 α -carbons (Fig. 2b). The CdiA-CT/CdiI^{YPIII} complex also contains a β -augmentation interaction in which the toxin extends its $\beta 4/\beta 5$ -hairpin into binding pocket within the immunity protein (Fig. 2a and b). However, in contrast to CdiA-CT_{o11}^{EC869}, which contains an ordered Zn²⁺ ion in the active site [7], no zinc was detected by metal K-edge absorption analysis of multiple CdiA-CT/CdiI^{YPIII} crystals and the electron density spheres within the active-site vicinity of CdiA-CT^{YPIII} were not within zinc coordinating distances with the catalytic residues or would form a zinc tetracoordination or hexacoordination sphere and thus were modeled as water molecules (Fig. S2).

CdiA-CT^{YPIII} and CdiI^{YPIII} bind one another through a network of 14 direct H-bonds and ion pairs (Table S1) combined with several hydrophobic interactions. Only two CdiA-CT^{YPIII} β -hairpin side chains (Glu242 and Lys243) interact directly with CdiI^{YPIII}, compared to the six direct side-chain interactions in the CdiA-CT/CdiI_{o11}^{EC869} complex (Table S1 and Fig. 3). The CdiA-CT/CdiI^{YPIII} β -hairpin pocket also contains a network of bridging water molecules and several more hydrophobic interactions than the CdiA-CT/CdiI_{o11}^{EC869} complex (Fig. 3). In addition, extensive interactions outside of the β -augmentation region contribute to CdiA-CT/CdiI^{YPIII} complex stability. Loop L1 of CdiA-CT^{YPIII} forms several hydrophobic contacts with the elongated loop of CdiI^{YPIII}. Residue Lys195 within L1 forms a salt-bridge with CdiI^{YPIII} residue Glu137 within $\beta 6$. The loop connecting strands $\beta 2$ and $\beta 3$ also has several H-bond interactions and Asp201 forms a prominent salt-bridge with Arg69 in the elongated loop of CdiI^{YPIII} (Table S1 and Fig. 2 b). In contrast, the CdiA-CT/CdiI_{o11}^{EC869} complex has a less extensive interaction network outside of the β -augmentation region. Loop L1 of CdiA-CT_{o11}^{EC869} has fewer hydrophobic contacts and one ionic interaction between Asp183 and Arg71 of CdiI_{o11}^{EC869} (Table S1). Together, these structures reveal overall conservation between the toxin/immunity protein pairs but reveal important differences in the network of bonds that stabilize each complex (Fig. S3).

CdiI_{o11}^{EC869} and CdiI^{YPIII} immunity proteins are specific for their cognate toxins

The conservation of nuclease active-site residues strongly suggests that CdiA-CT^{YPIII} has DNase activity similar to that described for CdiA-CT_{o11}^{EC869} [7]. We isolated the CdiA-CT^{YPIII} domain from its immunity protein and tested for DNase activity *in vitro* using supercoiled plasmid as a substrate. CdiA-CT^{YPIII} had no detectable nuclease activity in the presence of Mg²⁺ ions, but it converted the supercoiled plasmid into open-circular form when the reactions were supplemented with Zn²⁺ (Fig. 4). CdiA-CT^{YPIII} appears to be less

active than the CdiA-CT₀₁₁^{EC869} toxin, which had detectable DNase activity with Mg²⁺ and completely degraded the plasmid in the presence of Zn²⁺ ions (Fig. 4). We next tested the CdiI^{YPIII} and CdiI₀₁₁^{EC869} immunity proteins for the ability to neutralize DNase activity *in vitro*. Each immunity protein was able to partially block the activity of its cognate toxin but had no effect on non-cognate toxin activity (Fig. 4). These results strongly suggest that each immunity protein only binds to its cognate toxin. We measured the dissociation constants (K_d) for cognate and non-cognate complexes using biolayer interferometry. CdiA-CT^{YPIII} and CdiI^{YPIII} form a high-affinity complex with $K_d = 16 \pm 1$ nM, which is similar to the value (18 ± 7 nM) previously reported for the CdiA-CT/CdiI₀₁₁^{EC869} complex [7]. In contrast, CdiI^{YPIII} has ~ 1000-fold lower affinity for non-cognate CdiA-CT₀₁₁^{EC869} with a K_d of 13 ± 2 μ M. This highly reduced affinity between CdiA-CT₀₁₁^{EC869} and CdiI^{YPIII} compared to cognate protein pairs is perhaps due, in part, to the shape and electrostatic incompatibility of the CdiA-CT₀₁₁^{EC869} β -hairpin with the binding pocket of CdiI^{YPIII} immunity protein (Fig. S4).

Immunity proteins only provide protection against their cognate toxins during CDI

The CdiA-CT^{YPIII} toxin is encoded within a defective *cdi* locus that has been inactivated by complex gene rearrangements and deletions. To ascertain whether the toxin is functional in cell-mediated CDI, we fused the CdiA-CT^{YPIII} nuclease domain to the C-terminus of CdiA^{EC93} and tested the resulting chimera for inhibition activity against *E. coli* target cells. Inhibitor cells that express the CdiA^{EC93}-CT^{YPIII} chimera reduced viable target-cell counts more than 500-fold after 4 h of co-culture, but target cells that express the cognate CdiI^{YPIII} immunity protein were completely protected from inhibition (Fig. 5a). In contrast, target cells that express CdiI₀₁₁^{EC869} immunity protein were inhibited to the same extent as cells that lack any immunity gene (Fig. 5a). Similarly, the CdiI^{YPIII} immunity protein was unable to protect target cells from inhibitor cells that deploy the CdiA-CT₀₁₁^{EC869} toxin (Fig. 5a). We also examined competition co-cultures by fluorescence microscopy to detect DNase activity in target bacteria. We labeled inhibitor cells with yellow fluorescent protein (YFP) and target cells with mKate2 to differentiate the two populations and also stained the cells with 4',6-diamidino-2-phenylindole (DAPI) to visualize nucleoids. Immediately after cell mixing, both inhibitor-cell and target-cell populations had similar morphologies and nucleoid staining was uniform (Fig. 5b). After 4 h of co-culture, target cells that lack the appropriate immunity protein became filamentous and lost DAPI staining (Fig. 5b and Fig. S5), indicating significant damage to the chromosome. In contrast, target cells that express cognate CdiI immunity proteins retained normal morphology and DAPI staining (Fig. 5b and Fig. S5). Together, these data demonstrate that these two toxin/immunity systems have diverged into distinct non-overlapping immunity groups.

β -Augmentation is required for toxin/immunity protein complex formation

The β -augmentation interactions observed in the two toxin/immunity protein complexes suggest that the proteins bind using a lock-and-key mechanism. Therefore, we sought to crystallize and solve the structures of isolated toxins and immunity proteins to determine if the proteins undergo any conformational changes upon complex formation. Neither of the isolated toxin domains formed crystals, but we were able to crystallize and solve the 1.8-Å

structure of an isolated immunity protein (CdiI^{Ykris}) encoded by the Ykris_10740 locus of *Yersinia kristensenii* ATCC 33638 (Table 1). CdiI^{Ykris} shares 68.9% and 51.5% sequence identity with CdiI^{EC869}_{o11} and CdiI^{YPIII} (respectively) (Fig. 1c), and its structure superimposes onto CdiI^{EC869}_{o11} and CdiI^{YPIII} with rmsd of 0.626 and 0.984 Å over all α-carbons (respectively) (Fig. S6). In addition, structural homology searches identified yet another immunity protein homologue (CdiI^{NMB}) encoded by the NMB0488 locus in *Neisseria meningitidis* MC58 (PDB code: 2GKP). CdiI^{NMB} superimposes onto each of the other immunity proteins with rmsd values <0.7 Å over all α-carbons (Fig. S6). Collectively, these structures indicate that CdiI^{EC869}_{o11} homologues retain the same architecture of the β-hairpin binding pocket in the absence of bound toxin. This finding suggests that β-hairpins are modular, raising the possibility that interaction specificity could be altered by exchanging β4/β5 (β-hairpin) sequences between toxins.

To test whether β-augmentation is required for stable complex formation, we replaced the CdiA- CT^{EC869}_{o11} β-hairpin (residues Lys242–Thr252) with a Gly-Ser-Gly peptide linker to generate CdiA- CT^{EC869/Δβ4β5}_{o11} (Fig. 6a). Wild-type CdiA- CT^{EC869}_{o11} binds to its cognate immunity protein with nanomolar affinity and co-purifies with His₆-tagged CdiI^{EC869}_{o11} during Ni²⁺-affinity chromatography (Fig. 6b). In contrast, CdiA- CT^{EC869/Δβ4β5}_{o11} did not co-purify with His₆-tagged CdiI^{EC869}_{o11} (Fig. 6b), suggesting that the mutant domain has lower affinity for immunity protein. We purified CdiA- CT^{EC869/Δβ4β5}_{o11} to homogeneity by anion-exchange chromatography and measured its affinity for CdiI^{EC869}_{o11}-His₆ using biolayer interferometry. However, no binding interaction was detected, indicating that the dissociation constant is >300 μM. To test whether deletion of the β-hairpin disrupts toxin structure, we examined the CdiA- CT^{EC869/Δβ4β5}_{o11} domain using circular dichroism (CD) spectroscopy. This analysis revealed that CdiA- CT^{EC869/Δβ4β5}_{o11} has essentially the same secondary-structure content as the wild-type domain (Fig. 6c). Taken together, these results demonstrate that the CdiA- CT^{EC869}_{o11} β-hairpin is critical for complex formation. Moreover, despite the very low affinity of CdiI to CdiA- CT^{EC869/Δβ4β5}_{o11}, a high level of expression of CdiA- CT^{EC869/Δβ4β5}_{o11} was observed (Fig. 6b) together with healthy cell growth, suggesting that the β-hairpin is also required for toxic DNase activity. This was confirmed by testing *in vitro* DNase activity in the presence of super-coiled plasmid DNA and Zn²⁺, which showed that the CdiA- CT^{EC869/Δβ4β5}_{o11} domain had no observable DNase activity (data not shown).

We next asked whether CdiI binding specificity can be altered by grafting heterologous β-hairpins onto the CdiA- CT^{EC869}_{o11} toxin. Using a catalytically inactive version of CdiA- CT^{EC869}_{o11} that contains the Asp198Ala mutation, we replaced residues Lys242–Glu250 with the corresponding sequences from homologous toxins from *Y. kristensenii* ATCC 33638 (CdiA-CT^{Ykris} encoded by ykris0001_10730) and *Neisseria lactamica* ATCC 23970 (CdiA-CT^{Nlact} encoded by NEILACOT_05635) (Fig. 7a). We co-expressed CdiA- CT^{EC869/Nlact}_{o11} and CdiA- CT^{EC869/Ykris}_{o11} together with His₆-tagged CdiI^{EC869}_{o11} and

purified the tagged immunity protein by Ni²⁺-affinity chromatography. Chimeric CdiA- CT_{o11}^{EC869/Nlact} toxin co-purified with His₆-tagged CdiI_{o11}^{EC869}, but CdiA- CT_{o11}^{EC869/Ykris} eluted in the void volume of the column (Fig. 7b). These results suggest that CdiA- CT_{o11}^{EC869/Nlact} binds with relatively high affinity to CdiI_{o11}^{EC869}, whereas the CdiA- CT_{o11}^{EC869/Ykris} toxin does not. We first confirmed that each chimeric toxin was folded properly using CD spectroscopy (Fig. 7c), then measured binding affinities for CdiI_{o11}^{EC869} using biolayer interferometry. CdiA- CT_{o11}^{EC869/Nlact} and CdiA- CT_{o11}^{EC869/Ykris} bound to CdiI_{o11}^{EC869} with dissociation constants of 180 ± 100 nM and 46 ± 36 μM, respectively (Table 2), consistent with the co-purification data. The difference in affinities of the *N. lactamica* and *Y. kristensenii* chimeric toxins for the CdiI_{o11}^{EC869} immunity protein is in part due to the differences in electrostatic and shape complementarity (Fig. S7). The *N. lactamica* and EC869 β-hairpins share similar electrostatics and shape (Fig. S7a and b), allowing CdiA- CT_{o11}^{EC869/Nlact} to retain nanomolar affinity for CdiI_{o11}^{EC869} (Table 2). In contrast, the *Y. kristensenii* β-hairpin has a different shape and altered electrostatics compared with CdiA- CT_{o11}^{EC869}, which results in low micromolar affinity of chimeric CdiA- CT_{o11}^{EC869/Ykris} toxin for CdiI_{o11}^{EC869} (Fig. S7a and c). We then tested whether the grafted β-hairpins confer higher affinity for CdiI^{Nlact} and CdiI^{Ykris} immunity proteins. The CdiA- CT_{o11}^{EC869/Ykris} chimera bound to CdiI^{Ykris} with about the same affinity as CdiI_{o11}^{EC869}, but somewhat surprisingly, this domain bound to CdiI^{Nlact} with ~10-fold higher affinity (Table 2). The CdiA- CT_{o11}^{EC869/Nlact} domain bound to CdiI^{Nlact} with essentially the same affinity as for CdiI_{o11}^{EC869} and interacted with CdiI^{Ykris} with approximately 10-fold lower affinity (Table 2).

Structure of the MAC/CdiI_{o11}^{EC869} complex

In principle, molecules that disrupt CdiA-CT/CdiI complexes should liberate the toxin domain and induce CDI⁺ bacteria to undergo auto-inhibition. Nowick and coworkers have previously developed macrocyclic peptides containing δ-linked ornithine turn units that adopt a β-hairpin conformation and should be suitable to disrupting the CdiA-CT/CdiI complex [16,17]. To test the feasibility of this strategy, we designed a macrocyclic peptide (MAC) that mimics the β-hairpin of CdiA- CT_{o11}^{EC869}. The MAC peptide contains residues corresponding to Lys242–Ser253 of CdiA- CT_{o11}^{EC869}, which were connected through a δ-linked ornithine residue (Fig. S1). Biolayer interferometry experiments failed to detect a binding interaction between MAC and CdiI_{o11}^{EC869}; the MAC peptide was unable to promote DNase activity when added in ~10³-fold molar excess to the CdiA- CT/CdiI_{o11}^{EC869} complex *in vitro* (data not shown). Despite its low affinity for CdiI_{o11}^{EC869}, we were able to crystallize the MAC peptide in complex with the immunity protein and solve the structure to 2.0 Å resolution by molecular replacement (Fig. 8a). As anticipated, the MAC peptide forms a two-stranded β-sheet, though there are only four cross-strand H-bonds compared to the five in the CdiA- CT/CdiI_{o11}^{EC869} complex. The ornithine turn creates a bulge that prevents

formation of the fifth H-bond (Fig. 8b). The MAC/CdiI^{EC869}_{o11} structure superimposes well with CdiI^{EC869}_{o11} (rmsd of 0.437 Å over all α -carbons), though helix $\alpha 3^*$ is displaced 3.0 Å to create a slightly altered β -hairpin binding pocket (Fig. 8b). Five MAC peptide side chains form H-bonds or ion-pair interactions with the immunity protein, in contrast to the six direct interactions observed in the CdiA-CT/CdiI^{EC869}_{o11} complex. In the CdiA-CT/CdiI^{EC869}_{o11} complex, β -hairpin residue Ser247 interacts with the immunity protein. However, the corresponding Ser7 residue within the MAC peptide does not interact with CdiI^{EC869}_{o11} (Fig. 8c). Additionally, the side-chain conformation of MAC residue Arg10 is altered compared to that of Arg249 in the CdiA-CT/CdiI^{EC869}_{o11} structure, resulting in a H-bond interaction with the hydroxyl of Ser80 rather than the backbone carbonyl of Phe75 in the toxin/immunity structure. The MAC/CdiI^{EC869}_{o11} structure establishes that structure-based designed macrocyclic peptides can bind in the CdiI^{EC869}_{o11} β -hairpin binding pocket (Fig. 8d), forming contacts that mimic those found in the CdiA-CT/CdiI complexes.

Discussion

CDI toxin/immunity protein pairs are diverse and comprise more than 100 distinct families. Even within a given family, there is considerable sequence variability suggesting that toxin/immunity protein families continue to evolve. This phenomenon is well illustrated by homologues of the CdiA-CT/CdiI^{EC869}_{o11} toxin/immunity protein pair. Alignment of 26 closely related toxin domains from this family reveals that nearly all of the secondary-structure elements are highly conserved (Fig. S3a). The obvious exception is the $\beta 4/\beta 5$ -hairpin, which mediates the β -augmentation interaction and is the least conserved element in the family. Loop L1 of the toxin domain is responsible for all other contacts with the immunity protein; however, in contrast to the β -hairpin, this region is well conserved with five invariant residues (Arg189, Leu190, Pro19, Phe194 and Asp198). Although loop L1 is highly conserved, it interacts with immunity proteins using distinct contacts in the CdiA-CT/CdiI^{EC869}_{o11} and CdiA-CT/CdiI^{YPIII} complexes. Loop L1 of CdiA-CT/CdiI^{EC869}_{o11} engages almost exclusively in hydrophobic and van der Waals interactions, whereas the C-terminal portion of the CdiA-CT^{YPIII} loop is dominated by direct H-bond and ion-pair interactions involving residues Asp201, Ala203 and Thr204. The differences are striking because these three residues are also present in CdiA-CT/CdiI^{EC869}_{o11} yet do not form the same interactions. Similar phenomena are observed for the immunity proteins. CdiI strand $\beta 3^*$ anneals with the toxin's variable $\beta 5$ strand during β -augmentation; accordingly, $\beta 3^*$ varies between immunity proteins in the family (Fig. S3b). However, CdiI strands $\beta 7^*$, $\beta 8^*$ and $\beta 9^*$ and the intervening loops are highly conserved, yet this region interacts with cognate toxins using distinct molecular contacts. In several instances, highly conserved residues engage in direct H-bonds in one complex but fail to make any intermolecular contact in another closely related complex. Therefore, even conserved sequence elements can be exploited to discriminate against near-cognate partners. The idiosyncratic nature of these interactions most likely explains why immunity binding specificity cannot be switched through a simple exchange of $\beta 4/\beta 5$ -hairpins between homologous toxins.

The divergence of toxin/immunity protein interactions was first recognized and characterized in a subset of E-class colicins. Colicins are diffusible protein toxins released by some strains of *E. coli* to kill other competing bacteria [18]. Though colicins and CdiA proteins are not related, there are several features common to both competition systems. One striking parallel is the variability of C-terminal toxin domains. The eight characterized E-class colicins share nearly identical N-terminal domains, but their C-terminal nuclease domains are distinct with DNase (E2, E7, E8 and E9), ribosomal RNase (E3, E4 and E6) or tRNase (E5) activities [18]. Like CdiA proteins, colicins are always encoded in tandem with a specific immunity protein that binds the nuclease domain and blocks its activity. Colicins E2, E7, E8 and E9 carry homologous DNase domains, yet their respective immunity proteins do not protect against near-cognate toxins [19,20]. Structure–function analyses show that E-class immunity proteins bind to a contiguous stretch of ~30 residues that are highly variable between the different nuclease domains [21–23]. Similarly, the interaction surfaces on the immunity proteins are also variable but contain a conserved core interaction comprised of Tyr54 and Tyr55 (ImE9 numbering) [21,24]. This invariant core provides significant binding energy and near-cognate colicin toxin/immunity protein interactions often have dissociation constants of 10^{-8} M [25], which are similar in affinity to the cognate CdiA-CT/CdiI complexes studied here. An analogous core interaction centered at the tip of the β -hairpin is found in the CdiA-CT/CdiI^{EC869}_{o11} toxin/immunity family. Leu246 of the toxin engages in a hydrophobic interaction with an aliphatic residue in the immunity protein (Ala131 in CdiI^{EC869}_{o11} and Val141 in CdiI^{YPIII}). Similarly, toxin residue Ser247 interacts with a Tyr residue (Tyr84 in CdiI^{EC869}_{o11} and Tyr94 in CdiI^{YPIII}) that is invariant in the immunity protein family (Fig. S3b). However, these core interactions do not provide significant binding affinity for near-cognate toxin/immunity pairs. A final important parallel between the colicin E-class and CdiA-CT^{EC869}_{o11} DNases is that both the immunity proteins bind to exosites, leaving the nuclease active site exposed in the toxin/immunity complex [7,18]. The spatial segregation of substrate and immunity binding sites presumably provides the flexibility to evolve unique protein–protein interactions while retaining catalytic activity. The fact that two unrelated DNase toxin/immunity pairs appear to be diverging rapidly suggests that this is a general and perhaps universal feature of toxin/immunity systems.

Protein–protein interactions presumably evolve through mutational drift followed by reciprocal changes in the binding partner to maintain overall affinity while the underlying molecular contacts change. Riley and colleagues have proposed a diversification–selection model to explain the observed diversity in E-class colicin/immunity protein pairs. According to their model, some mutations expand immunity function and allow the newly evolved immunity protein to protect not only against its cognate toxin but also against the colicins released by other strains [26,27]. Such mutations would appear to be rare but have been identified and characterized experimentally [28,29]. One striking example that supports this model is the Asp33Leu mutation in ImE2 immunity protein, which increases affinity for non-cognate colicin E9 more than a 3000-fold [29]. The advantage conferred by the new immunity gene would provide the selective pressure to retain the allele and allow it to become fixed in the population. This in turn allows for subsequent mutations in the linked colicin gene. Further mutations in the colicin are predicted to produce “super-killer” toxins,

to which the ancestral bacteria are not immune [27]. Thus, the evolved colicin/immunity pair kills ancestral cells, thereby allowing fixation of the new pair in the population. Multiple iterations of this process are predicted to eventually produce a family of divergent toxin/immunity pairs. Of course, mutations that disrupt the toxin/immunity protein complex should be lethal to the cell; thus, the pressure to retain high-affinity interactions is presumably a significant barrier to diversification. However, colicin/immunity protein complexes have some of the highest known binding affinities, with cognate pairs characterized by femto-molar dissociation constants [22,25,29,30]. Therefore, even if a mutation results in a 1000-fold decrease in affinity, the complex will still have a sub-nanomolar dissociation constant, which is sufficient to provide complete protection against toxicity [25,30]. Thus, the extraordinarily high affinity of cognate colicin/immunity protein complexes provides a buffer against the potentially lethal effects of mutations that disrupt the toxin/immunity protein interface. In contrast, the CDI toxin/immunity proteins studied here have much lower binding affinities with dissociation constants of about 20 nM for cognate pairs. Therefore, CDI toxin/immunity systems must exploit other biophysical mechanisms to avoid self-intoxication during evolution. One possible mechanism involves the over-expression of immunity proteins relative to the toxins. The majority (21 of 25) of CdiA-CT^{EC869}_{o11} homologues presented in Fig. S3a are encoded by truncated *cdiA* gene fragments that lack the N-terminal coding sequences required for secretion. These pseudogene pairs are termed “orphan” modules because they resemble *cdiA-CT/cdiI* coding sequences that have been displaced from full-length *cdiA* genes [9]. Orphan *cdiA-CT* reading frames usually lack translation initiation signals, whereas the linked orphan *cdiI* genes have canonical ribosome binding sites upstream of the initiating Met codon. These observations suggest that the toxins are expressed at very low levels, but the immunity proteins are highly expressed. Under these conditions, the selective pressure to retain immunity function would be relieved and allow the immunity gene to undergo drift without lethal consequences. This hypothetical scenario is supported by the observation that non-cognate/mutated immunity proteins can fully protect cells when over-expressed [25,31]. Therefore, we propose that the organization of *cdiA-CT/cdiI* gene pairs into orphan modules serves to accelerate toxin/immunity evolution by attenuating toxin expression. We note that this could be a general strategy to generate diversity in inter-bacterial competition systems because similar clusters of orphan gene pairs are associated with *rhs* genes in type VI secretion systems [9,32] and the *mafB* genes of *Neisseria* species [33].

CDI systems are widespread throughout proteo-bacteria and are most commonly found in pathogenic species, such as *Yersinia pestis*, *N. meningitidis* and *B. pseudomallei* [2,34]. Because CDI⁺ bacteria exchange CdiA-CT toxins with one another, it may be possible to induce bacterial suicide with small molecules that specifically disrupt CDI toxin/immunity protein binding interactions. The β -hairpin binding pocket within CdiI^{EC869}_{o11} and homologous immunity proteins is an attractive target to test this antimicrobial strategy. Small cyclic peptides that fold into β -hairpins have been used to study protein–protein and protein–DNA interactions and, in some instances, have been used to specifically disrupt protein complexes [35,36]. As illustrated by the MAC/CdiI^{EC869}_{o11} structure, cyclic β -hairpin mimics can be designed to bind CdiI immunity proteins. Our design could be improved to enhance binding affinity and possibly be utilized as a protein–protein complex inhibitor by increasing the

number of residues or designing additional contacts. Although the current MAC contains pentapeptide strands, we have previously reported cyclic β -hairpin mimics containing heptapeptide and nonapeptide β -strands [37,38]. Homologous MACs containing larger β -hairpin mimics and designed to achieve more contacts may allow rational design of a higher affinity macrocyclic peptide that specifically may disrupt toxin/immunity complexes within bacterial pathogens, setting the stage for the development of a new class of antibacterials.

Materials and Methods

Bacterial strains and plasmid constructs

All bacterial strains and plasmids used in this study are presented in Table S2. All primers used in this study are presented in Table S3. YFP-labeled *E. coli* EPI100 cells were generated by integrating the *yfp* coding sequence at the *gal* locus. First, a genomic integration construct was made by amplifying the kanamycin-resistance cassette from plasmid pKAN [39] with primers Kan-1/Kan-2, followed by blunt-end ligation to SmaI-digested plasmid pBluescript. One plasmid clone was identified with the kanamycin-resistance cassette in the opposite orientation as pKAN, and this plasmid was termed pNAK. A fragment of *galM* was then amplified using primers CH3789/ CH3790, and the product was ligated to SacI/BamHI-digested plasmid pNAK to produce pCH2500. A *yfp-galT* fragment was amplified from *E. coli* DA28100 (a gift from Sanna Koskiniemi, Uppsala University) using primers CH3787/CH3788, digested with KpnI/EcoRI and then ligated into pCH2500 to yield plasmid pCH2503. The large KpnI/SacI fragment from pCH2503 was recombined into *E. coli* EPI100 cells that harbor plasmid pSIM6 as described previously [40,41]. mKate2-labeled target bacteria were generated by integrating the coding sequence of mKate2 at the phage HK022 *attP* site using plasmids pDE1013 and pAH69 as described previously [42].

The coding sequence for CdiA-CT/CdiI^{YPIII} was amplified from *Y. pseudotuberculosis* YPIII genomic DNA with primers YPK0575-Kpn-for/YPK0576-Xho-rev. The resulting product was digested with KpnI/XhoI and ligated pET21S to generate plasmid pCH10413. The CdiA-CT^{EC869/ Δ _{64,65}} expression construct was generated by replacing the β 4/ β 5-hairpin coding sequence with a Gly-Ser linker. The 5'-end of the construct was amplified with primers β -deletion-for1/ β -deletion-rev1 and the 3'-end with primers β -deletion-for2/ β -deletion-rev2. The two PCR fragments were ligated at the BamHI site, and the joined fragments re-amplified with β -deletion-for1/ β -deletion-rev2. The resulting product was ligated to pET21d using NcoI and XhoI restriction sites to generate pCH10369. Catalytically inactive CdiA-CT^{EC869}₆₁₁ domains carrying the Asp198Ala mutation and heterologous β -hairpin sequences were generated by PCR. Plasmid pCH10164 was amplified with primers EC869-CT-Nco/ EC869-Nlact(beta)-rev and EC869-Nlact(beta)-for/ EC869-cdiI-Spe, and the two products combined by overlap extension PCR (OE-PCR) [43] using primers EC869-CT-Nco/EC869-cdiI-Spe. The final product was digested with NcoI/SpeI and ligated to pET21S to generate plasmid pCH10365. The same procedure was used to introduce the *Y. kristensenii* β -hairpin by PCR with primers EC869-CT-Nco/EC869-Ykris(beta)-rev and EC869-Ykris (beta)-for/EC869-cdiI-Spe. The two products were combined by OE-PCR and ligated to pET21S to generate plasmid pCH10175. The coding sequences for CdiI^{Ykris}

(ykris0001_10740) and CdiI^{Nlact} (NEILACOT_05636) were chemically synthesized (GenScript, Inc.) with flanking restriction sites and ligated to plasmid pUC57. The ykris0001_10740 sequence was subcloned into pTrc99KX to generate plasmid pCH10103, which was then used as a template for PCR with primers pTrc-seq2/Ykris-cdiI-Spe-rev. The resulting product was digested with KpnI/SpeI and ligated to pET21K to generate plasmid pCH10170. The NEILACOT_05636 sequence was subcloned into pCH450 to generate plasmid pCH10101, which was then used as a template for PCR with primers pCH450-for/Nlact-cdiI-Spe-rev. The resulting product was digested with NcoI/ SpeI and ligated to pET21S to generate plasmid pCH10172.

The chimeric CDI system that deploys CdiA-CT^{YPIII} toxin was generated by replacing the CdiA-CT_{o11}^{EC869} DNase domain with the corresponding region of CdiA-CT-^{YPIII}. Regions upstream and downstream of the *cdiA-CT/cdiI*^{EC869} sequence were amplified from plasmid pCH9305 using primers DL1527/EC869o11-G173-rev (upstream) and EC93-YPIII-down-for/DL2368 (downstream). The *cdiA-CT/cdiI*^{YPIII} sequence was amplified from *Y. pseudotuberculosis* YPIII genomic DNA using primers EC869o11-G173-for/EC93-YPIII-chim-rev. The three PCR products were combined by OE-PCR using primers DL1527/DL2368. The final product was electroporated together with plasmid pCH10163 into *E. coli* strain DY378 as described previously [7,8]. Recombinants were selected on yeast extract/ glucose-agar supplemented with 33 µg/mL chloram-phenicol and 10 µM D/L-*o*-chlorophenylalanine. All plasmid constructs were verified by DNA sequence analysis.

Protein purification

All proteins were over-produced from pET21-derived plasmid using either *E. coli* CH2016 or *E. coli* BL21-Gold(DE3). Cells were grown aerobically at 37 °C in LB medium containing 150 µg/mL ampicillin. CdiA-CT/CdiI-^{YPIII} expression was induced by the addition of 1 mM isopropyl-β-D-thiogalactoside at OD₆₀₀ ~ 0.8 and grown for a further 3–4 h before harvesting. Cells were collected by centrifugation at 5500g for 25 min and then washed with resuspension buffer [20 mM sodium phosphate (pH 7.0) and 150 mM NaCl]. Cells were resuspended and disrupted by sonication on ice in resuspension buffer containing 10 mg/mL lysozyme and 1 mM phenylmethyl-sulfonyl fluoride. Cell debris was removed by centrifugation at 18,000g for 30 min followed by filtration through a 1.0-µm filter. Clarified lysates were loaded onto a Ni²⁺-charged HiTrap column (5 mL; GE Healthcare) or Ni²⁺-nitrilotriacetic acid (Ni²⁺-NTA) agarose resin (MCLAB) and washed with resuspension buffer supplemented with 10 mM imidazole. Proteins were eluted with a linear gradient of imidazole (10–500 mM) in resuspension buffer. Fractions were collected, combined and concentrated to a volume of ~500 µL using a 10-kDa centrifugal concentrator (Centricon; Millipore). Proteins were further purified by gel filtration on a Superdex 200 column for the CdiA-CT/CdiI^{YPIII} complex or on a Superdex 75 for individual immunity proteins (GE Healthcare). Gel-filtration columns were equilibrated with 20 mM sodium phosphate (pH 7.0) and 150 mM NaCl using an AKTA FPLC. Purification of CdiI^{Ykris} and CdiI_{o11}^{EC869} followed the same protocol, except that all buffers contained 20 mM Tris-HCl (pH 7.4) instead of sodium phosphate. CdiA-CT/CdiI^{YPIII}, CdiI^{Ykris} and CdiI_{o11}^{EC869} were concentrated to 10, 12.5 and 7.5 mg/mL (respectively) for crystallization trials.

The individual His₆-tagged CdiI proteins were over-produced from plasmid pET21d constructs and purified as described above for CdiI_{o11}^{EC869}. CdiA-CT proteins were isolated from co-expressed His₆-tagged CdiI proteins by two methods, depending on whether the two proteins co-eluted following Ni²⁺-affinity chromatography. CdiA-CT/CdiI-His₆ complexes were denatured overnight in 6 M urea and then subjected to Ni²⁺-affinity chromatography in buffers containing 6 M urea. Denatured CdiA-CT toxins were collected from the void volume, refolded by dialysis into 20 mM Tris-HCl (pH 8.0) and 10 mM NaCl and then concentrated on a HiTrap Q anion-exchange column and eluted with a salt gradient, yielding 95% pure CdiA-CT protein. Purified toxins were then exchanged into 20 mM Tris-HCl (pH 7.4) and 150 mM NaCl by gel filtration on a S75 column.

Crystallization and structure determination

Protein crystals were grown by hanging-drop vapor diffusion, with drops containing a 1:1 ratio (vol/vol) of protein solution to reservoir liquor. Crystals were mounted and collected under cryo-conditions with the addition of 40% glycerol as cryoprotectant to the reservoir solution. Datasets were collected at 70 K at a wavelength of 1.0 Å and images were indexed, integrated and reduced using either iMOSFLM (CdiA-CT/CdiI^{YPIII} complex) [44] or the HKL2000 suite (CdiI^{Ykris} and MAC/CdiI_{o11}^{EC869}) [45]. Initial phases were determined by molecular replacement by autoMR in PHENIX using the CdiA-CT/CdiI_{o11}^{EC869} structure (PDB code: 4G6U) as a search model. Initial model building was performed by Autobuild in PHENIX. The final models were built through iterative manual building in Coot and refined with phenix.refine. Data collection and refinement statistics are presented in Table 1. All molecular graphics were prepared with PyMOL [46].

CdiA-CT/CdiI^{YPIII} crystals were grown from a solution (10 mg/mL) and a reservoir containing 50 mM Hepes (pH 7.0), 20% polyethylene glycol (PEG) 3350 and 1% tryptone. The complex crystallized in space group *C2* with unit cell dimensions 65.51 Å × 65.51 Å × 71.49 Å and one complex per asymmetric unit. The model contains residues Met174–Lys297 (numbered from Val1 of the VENN motif) of CdiA-CT^{YPIII} and residues Asp3–Lys176 of CdiI^{YPIII}. CdiA-CT^{YPIII} residues Lys182, Lys220, Lys240 and Lys297 were modeled as Ala due to lack of observable side-chain density. Similarly, CdiI^{YPIII} residues Asp3, Lys108, Lys118, Lys148 and Lys176 were modeled as Ala residues. The final CdiA-CT/CdiI^{YPIII} model includes 148 water molecules resulting in an $R_{\text{work}}/R_{\text{free}}$ (%) of 20.5/25.6 (Table 1). CdiI^{Ykris} immunity protein crystals were grown from a solution (12.5 mg/mL) over a reservoir containing 0.2 M ammonium fluoride and 20% PEG 3350. The crystal space group was *P3₁* with unit cell dimensions 54.448 Å × 54.448 Å × 54.472 Å and one molecule per asymmetric unit. The final model contains CdiI^{Ykris} residues Met1–Gly165 and 130 water molecules resulting in an $R_{\text{work}}/R_{\text{free}}$ (%) of 18.1/22.1. CdiI^{Ykris} residues Lys4, Glu67, Lys96, Lys126 and Lys136 were modeled as Ala due to lack of observable side-chain density. In addition, the CdiI^{Ykris}-His₆ expression construct contained an Ala84Thr mutation.

The macrocyclic peptide (MAC) that mimics the CdiA-CT_{o11}^{EC869} β-hairpin (Fig. S1) was prepared according to previously described procedures [16,47,48]. MAC peptide (2 mg) was

added to 200 μL of 7.5 mg/mL $\text{CdiI}_{011}^{\text{EC869}}$ to yield a solution at a ~10:1 peptide-to-protein ratio. MAC/ $\text{CdiI}_{011}^{\text{EC869}}$ co-crystals were grown over 2 days in 0.2 M sodium acetate (pH 5.6), 0.1 M 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol propane (pH 6.9) and 20% (wt/vol) PEG 3350, using the protein/peptide mixture previously described. Initial crystals were of poor quality and resulted in highly mosaic diffraction data. Crystal quality was improved by microseeding [49]. Briefly, crystals were harvested into 80 μL of crystallization solution and a seed stock was generated using a seed bead (Hampton). Following optimization, suitable diffraction-quality crystals were generated using a hanging drop containing 1 μL of seed stock and 1 μL of the protein/peptide mixture following a 3-fold dilution. The MAC/ $\text{CdiI}_{011}^{\text{EC869}}$ complex crystallized in space group $P2_1$ with unit cell dimensions 34.776 \AA \times 128.166 \AA \times 44.953 \AA (Table 1). Each asymmetric unit contained two MAC/ $\text{CdiI}_{011}^{\text{EC869}}$ complexes. The final model contains two molecules of $\text{CdiI}_{011}^{\text{EC869}}$ residues Ala2–Gly167, two macrocyclic peptides and 132 water molecules, resulting in $R_{\text{work}}/R_{\text{free}}$ (%) of 18.4/23.1. Residues Lys5, Gln43, Glu78, Lys85, Glu93 of one $\text{CdiI}_{011}^{\text{EC869}}$ molecule (chain D only), Asp117 and Glu139 of both $\text{CdiI}_{011}^{\text{EC869}}$ molecules were modeled as Ala due to lack of observable side-chain density.

Protein analyses

The secondary structure of purified toxins (0.1 mg/mL in 20 mM Tris–HCl, pH 7.4) was analyzed by CD spectroscopy on a Jasco J-720 spectropolarimeter using a 0.1-cm pathlength. Spectra were collected at 20 nm/min with a 2-nm bandwidth and a 4-s response time. Three consecutive scans were collected and averaged for each analysis. CdiA-CT/ CdiI binding affinities were determined by biolayer interferometry as described previously [7]. Binding reactions were performed at 25 $^{\circ}\text{C}$ in 20 mM Tris–HCl (pH 7.4) and 150 mM NaCl. CdiI -His₆ immunity proteins were immobilized onto Ni²⁺-NTA biosensors and exposed to cognate or heterologous CdiA-CT toxins at 0.5–300 μM . A reference was subtracted from all binding curves before curve fitting. Curve fitting and data processing were performed using BLitz Pro software (ForteBio, Inc.).

In vitro analysis of nuclease activities

The activities of purified $\text{CdiA-CT}_{011}^{\text{EC869}}$ and $\text{CdiA-CT}^{\text{YPIII}}$ were assayed *in vitro* using supercoiled plasmid pUC18 as a substrate. CdiA-CT (at 1 μM final concentration) was incubated with 250 ng of plasmid DNA in 20 mM Tris–HCl (pH 7.5), 100 mM NaCl and 0.1 mg/mL bovine serum albumin supplemented with 2 mM MgCl_2 or ZnCl_2 for 1 h at 37 $^{\circ}\text{C}$. Where indicated, purified CdiI -His₆ proteins were included at 2 μM final concentration and allowed to bind CdiA-CT for 30 min at room temperature prior to adding substrate DNA. Reactions were quenched with 10 mM ethylenediaminetetraacetic acid followed by the addition of 300 μL of denaturing solution (4 M guanidine HCl and 33% 2-propanol). The reactions were purified over silica membrane spin columns (Epoch Life Sciences). Columns were then washed with 70% ethanol and 10 mM Tris–HCl (pH 8.0) followed by elution with 10 mM Tris–HCl (pH 8.0). Purified DNA from reactions was run on 1% agarose gels containing ethidium bromide and visualized using Bio-Rad Gel Doc 2000.

Competition co-cultures and fluorescence microscopy

Inhibitor cells (*E. coli* EPI100 carrying plasmid pCH9305, pCH2409 or pDAL878) and target cells (CH8251 carrying plasmid pTrc99a, pCH9315 or pCH848) were grown individually in LB media with 33 $\mu\text{g}/\mu\text{L}$ Cm for inhibitors and 150 $\mu\text{g}/\mu\text{L}$ Amp for targets. The overnight cultures were diluted into fresh LB medium without antibiotics and grown in baffled flasks at 37 °C. At mid-log phase, the inhibitor and target strains were mixed together at a 1:1 ratio in baffled flasks and a sample was withdrawn to score viable target cells as colony-forming units per milliliter on LB agar supplemented with 200 $\mu\text{g}/\text{mL}$ rifampicin (Rif). After 4 h of co-culture, another sample was taken and viable target cells were enumerated on Rif-supplemented LB agar. Viable target-cell counts are the mean colony-forming units per milliliter \pm the standard error of the mean for three independent experiments. Competitions with fluorescent inhibitor and target bacteria were conducted as described above, except that YFP-labeled inhibitor CH2550 cells and mKate2-labeled targets cells were used. Cells were diluted into fresh LB medium and grown to late-log phase at 30 °C in the dark to maximize fluorescence. Inhibitor and target cells were mixed at a 1:1 ratio in baffled flasks and incubated at 37 °C with shaking in the dark for the duration of the experiment. Samples (equivalent to $\text{OD}_{600} = 0.2$) were removed at the indicated times and cells were collected by centrifugation. Cells were briefly resuspended in freshly prepared 4% formaldehyde in 1 \times phosphate-buffered saline, and the fixation reaction was quenched with 125 mM glycine. Fixed cells were washed with 1 \times phosphate-buffered saline and spotted onto a slide coated with poly-D-lysine (Gold Seal Fluorescent Antibody Rite-On Slides from Fisher prepared by coating with a 1% poly-D-lysine solution prior to addition of cells). Unbound cells were removed gently with Nanopure water, and the slides were treated with Fluorogel II with DAPI mounting medium (Fisher Scientific/EMS) and a coverslip was overlaid prior to imaging. Images were acquired on an Olympus fluorescent microscope with a 100 \times oil objective using an Optronics MacroFire digital microscope camera. Lightfield images were captured with a 12-ms exposure (gain 2) and DAPI images were acquired in grayscale with a 48-ms exposure (gain 2). Fluorescent images were captured in grayscale using a 502-ms exposure/gain 5 (for YFP) or a 1-s exposure/gain 5 (for mKate2). Images were overlaid and false-colored using Fiji [50], and stacked images were cropped to 400 \times 400 pixels using GIMP. The same microscope images used to display fluorescence were used to obtain cell length measurements. Cells were manually measured using the line tool in Fiji, and between 175 and 328 cells from three microscopy fields were measured for each co-culture competition. Each object plotted represents a single cell length measurement. *P* values were obtained using two-tailed unpaired *t* tests.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the National Institutes of Health (GM102318 to C.S.H. and C.W.G.) and the National Science Foundation (CHE-1058825 to J.S.N. and DGE-1144085 to J.L.E.W.). Structure determination was, in part, supported by the Advanced Light Source (U.S. Department of Energy under Contract No. DE-AC02-05CH11231) at Berkeley National Laboratories and the Stanford Synchrotron Radiation Lightsource (supported in part by National Institutes of Health P41 GM103393 and U.S. Department of Energy DE-

AC02-76SF00515). Funding for open access charge is from National Institutes of Health. We would like to thank the staff at Advanced Light Source and Stanford Synchrotron Radiation Light-source for their invaluable help in data collection. We would also like to thank Elias Gerrick and Sonya Donato for technical support. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Abbreviations used

CDI	contact-dependent growth inhibition
DAPI	4',6-diamidino-2-phenylindole
YFP	yellow fluorescent protein
OE-PCR	overlap extension PCR
PEG	polyethylene glycol

References

1. Aoki SK, Pamma R, Hernday AD, Bickham JE, Braaten BA, Low DA. Contact-dependent inhibition of growth in *Escherichia coli*. *Science*. 2005; 309:1245–1248. [PubMed: 16109881]
2. Aoki SK, Diner EJ, de Roodenbeke CT, Burgess BR, Poole SJ, Braaten BA, Jones AM, Webb JS, Hayes CS, Cotter PA, Low DA. A widespread family of polymorphic contact-dependent toxin delivery systems in bacteria. *Nature*. 2010; 468:439–442. [PubMed: 21085179]
3. Aoki SK, Malinverni JC, Jacoby K, Thomas B, Pamma R, Trinh BN, Remers S, Webb J, Braaten BA, Silhavy TJ, Low DA. Contact-dependent growth inhibition requires the essential outer membrane protein BamA (YaeT) as the receptor and the inner membrane transport protein AcrB. *Mol Microbiol*. 2008; 70:323–340. [PubMed: 18761695]
4. Ruhe ZC, Wallace AB, Low DA, Hayes CS. Receptor polymorphism restricts contact-dependent growth inhibition to members of the same species. *mBio*. 2013; 4:e00480–13. [PubMed: 23882017]
5. Webb JS, Nikolakakis KC, Willett JL, Aoki SK, Hayes CS, Low DA. Delivery of CdiA nuclease toxins into target cells during contact-dependent growth inhibition. *PLoS ONE*. 2013; 8:e57609. [PubMed: 23469034]
6. Aoki SK, Webb JS, Braaten BA, Low DA. Contact-dependent growth inhibition causes reversible metabolic downregulation in *Escherichia coli*. *J Bacteriol*. 2009; 191:1777–1786. [PubMed: 19124575]
7. Morse RP, Nikolakakis KC, Willett JL, Gerrick E, Low DA, Hayes CS, Goulding CW. Structural basis of toxicity and immunity in contact-dependent growth inhibition (CDI) systems. *Proc Natl Acad Sci U S A*. 2012; 109:21480–21485. [PubMed: 23236156]
8. Beck CM, Morse RP, Cunningham DA, Iniguez A, Low DA, Goulding CW, Hayes CS. CdiA from *Enterobacter cloacae* delivers a toxic ribosomal RNase into target bacteria. *Structure*. 2014; 22:707–718. [PubMed: 24657090]
9. Poole SJ, Diner EJ, Aoki SK, Braaten BA, t'Kint de Roodenbeke C, Low DA, Hayes CS. Identification of functional toxin/immunity genes linked to contact-dependent growth inhibition (CDI) and rearrangement hotspot (Rhs) systems. *PLoS Genet*. 2011; 7:e1002217. [PubMed: 21829394]
10. Zhang D, de Souza RF, Anantharaman V, Iyer LM, Aravind L. Polymorphic toxin systems: Comprehensive characterization of trafficking modes, processing, mechanisms of action, immunity and ecology using comparative genomics. *Biol Direct*. 2012; 7:18. [PubMed: 22731697]
11. Nikolakakis K, Amber S, Wilbur JS, Diner EJ, Aoki SK, Poole SJ, Tuanyok A, Keim PS, Peacock S, Hayes CS, Low DA. The toxin/immunity network of *Burkholderia pseudomallei* contact-dependent growth inhibition (CDI) systems. *Mol Microbiol*. 2012; 84:516–529. [PubMed: 22435733]
12. Carr S, Walker D, James R, Kleanthous C, Hemmings AM. Inhibition of a ribosome-inactivating ribonuclease: The crystal structure of the cytotoxic domain of colicin E3 in complex with its immunity protein. *Structure*. 2000; 8:949–960. [PubMed: 10986462]

13. Soelaiman S, Jakes K, Wu N, Li C, Shoham M. Crystal structure of colicin E3: Implications for cell entry and ribosome inactivation. *Mol Cell*. 2001; 8:1053–1062. [PubMed: 11741540]
14. Gioia U, Laneve P, Dlakic M, Arceci M, Bozzoni I, Caffarelli E. Functional characterization of XendoU, the endoribonuclease involved in small nucleolar RNA biosynthesis. *J Biol Chem*. 2005; 280:18996–19002. [PubMed: 15755742]
15. Renzi F, Caffarelli E, Laneve P, Bozzoni I, Brunori M, Vallone B. The structure of the endoribonuclease XendoU: From small nucleolar RNA processing to severe acute respiratory syndrome coronavirus replication. *Proc Natl Acad Sci U S A*. 2006; 103:12365–12370. [PubMed: 16895992]
16. Woods RJ, Brower JO, Castellanos E, Hashemzadeh M, Khakshoor O, Russu WA, Nowick JS. Cyclic modular beta-sheets. *J Am Chem Soc*. 2007; 129:2548–2558. [PubMed: 17295482]
17. Nowick JS, Brower JO. A new turn structure for the formation of beta-hairpins in peptides. *J Am Chem Soc*. 2003; 125:876–877. [PubMed: 12537479]
18. Cascales E, Buchanan SK, Duche D, Kleanthous C, Lloubes R, Postle K, Riley M, Slatin S, Cavard D. Colicin biology. *Microbiol Mol Biol Rev*. 2007; 71:158–229. [PubMed: 17347522]
19. Cooper PC, James R. Two new E colicins, E8 and E9, produced by a strain of *Escherichia coli*. *J Gen Microbiol*. 1984; 130:209–215. [PubMed: 6368743]
20. Watson R, Rowsome W, Tsao J, Visentin LP. Identification and characterization of Col plasmids from classical colicin E-producing strains. *J Bacteriol*. 1981; 147:569–577. [PubMed: 7021534]
21. Kleanthous C, Kuhlmann UC, Pommer AJ, Ferguson N, Radford SE, Moore GR, James R, Hemmings AM. Structural and mechanistic basis of immunity toward endonuclease colicins. *Nat Struct Biol*. 1999; 6:243–252. [PubMed: 10074943]
22. Wojdyla JA, Fleishman SJ, Baker D, Kleanthous C. Structure of the ultra-high-affinity colicin E2 DNase–Im2 complex. *J Mol Biol*. 2012; 417:79–94. [PubMed: 22306467]
23. Ko TP, Liao CC, Ku WY, Chak KF, Yuan HS. The crystal structure of the DNase domain of colicin E7 in complex with its inhibitor Im7 protein. *Structure*. 1999; 7:91–102. [PubMed: 10368275]
24. Kleanthous C, Walker D. Immunity proteins: Enzyme inhibitors that avoid the active site. *Trends Biochem Sci*. 2001; 26:624–631. [PubMed: 11590016]
25. Li W, Keeble AH, Giffard C, James R, Moore GR, Kleanthous C. Highly discriminating protein–protein interaction specificities in the context of a conserved binding energy hotspot. *J Mol Biol*. 2004; 337:743–759. [PubMed: 15019791]
26. Riley MA. Positive selection for colicin diversity in bacteria. *Mol Biol Evol*. 1993; 10:1048–1059. [PubMed: 8412648]
27. Tan Y, Riley MA. Positive selection and recombination: Major molecular mechanisms in colicin diversification. *Trends Ecol Evol*. 1997; 12:348–351. [PubMed: 21238101]
28. Masaki H, Akutsu A, Uozumi T, Ohta T. Identification of a unique specificity determinant of the colicin E3 immunity protein. *Gene*. 1991; 107:133–138. [PubMed: 1743512]
29. Li W, Hamill SJ, Hemmings AM, Moore GR, James R, Kleanthous C. Dual recognition and the role of specificity-determining residues in colicin E9 DNase-immunity protein interactions. *Biochemistry*. 1998; 37:11771–11779. [PubMed: 9718299]
30. Wallis R, Leung KY, Pommer AJ, Videler H, Moore GR, James R, Kleanthous C. Protein–protein interactions in colicin E9 DNase-immunity protein complexes. 2. Cognate and noncognate interactions that span the millimolar to femtomolar affinity range. *Biochemistry*. 1995; 34:13751–13759. [PubMed: 7577967]
31. Levin KB, Dym O, Albeck S, Magdassi S, Keeble AH, Kleanthous C, Tawfik DS. Following evolutionary paths to protein–protein interactions with high affinity and selectivity. *Nat Struct Mol Biol*. 2009; 16:1049–1055. [PubMed: 19749752]
32. Koskiniemi S, Garza-Sanchez F, Sandegren L, Webb JS, Braaten BA, Poole SJ, Andersson DI, Hayes CS, Low DA. Selection of orphan Rhs toxin expression in evolved *Salmonella enterica* serovar typhimurium. *PLoS Genet*. 2014; 10:e1004255. [PubMed: 24675981]
33. Jamet A, Jousset AB, Euphrasie D, Mukorako P, Boucharlat A, Ducouso A, Charbit A, Nassif X. A new family of secreted toxins in pathogenic *Neisseria* species. *PLoS Pathog*. 2015; 11:e1004592. [PubMed: 25569427]

34. Ruhe ZC, Low DA, Hayes CS. Bacterial contact-dependent growth inhibition. *Trends Microbiol.* 2013; 21:230–237. [PubMed: 23473845]
35. Loughlin WA, Tyndall JD, Glenn MP, Fairlie DP. Beta-strand mimetics. *Chem Rev.* 2004; 104:6085–6117. [PubMed: 15584696]
36. Fasan R, Dias RL, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, Robinson JA. Using a beta-hairpin to mimic an alpha-helix: Cyclic peptidomimetic inhibitors of the p53-HDM2 protein–protein interaction. *Angew Chem Int Ed Engl.* 2004; 43:2109–2112. [PubMed: 15083458]
37. Cheng PN, Liu C, Zhao M, Eisenberg D, Nowick JS. Amyloid beta-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. *Nat Chem.* 2012; 4:927–933. [PubMed: 23089868]
38. Pham JD, Chim N, Goulding CW, Nowick JS. Structures of oligomers of a peptide from beta-amyloid. *J Am Chem Soc.* 2013; 135:12460–12467. [PubMed: 23927812]
39. Hayes CS, Bose B, Sauer RT. Proline residues at the C terminus of nascent chains induce SsrA tagging during translation termination. *J Biol Chem.* 2002; 277:33825–33832. [PubMed: 12105207]
40. Datta S, Costantino N, Court DL. A set of recombineering plasmids for Gram-negative bacteria. *Gene.* 2006; 379:109–115. [PubMed: 16750601]
41. Thomason, L.; Court, DL.; Bubunenko, M.; Costantino, N.; Wilson, H.; Datta, S.; Oppenheim, A. Recombineering: Genetic engineering in bacteria using homologous recombination. *Curr Protoc Mol Biol.* 2007. <http://dx.doi.org/10.1002/0471142727.mb0116s78>
42. Bonnet J, Subsoontorn P, Endy D. Rewritable digital data storage in live cells via engineered control of recombination directionality. *Proc Natl Acad Sci U S A.* 2012; 109:8884–8889. [PubMed: 22615351]
43. Aiyar A, Xiang Y, Leis J. Site-directed mutagenesis using overlap extension PCR. *Methods Mol Biol.* 1996; 57:177–191. [PubMed: 8850005]
44. Batty TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG. iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. *Acta Crystallogr D Biol Crystallogr.* 2011; 67:271–281. [PubMed: 21460445]
45. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* 1997; 276:307–326.
46. DeLano, WL. The PyMOL Molecular Graphics System, 1.3 ed. Schrödinger, LLC; 2010.
47. Cheng PN, Nowick JS. Giant macrolactams based on beta-sheet peptides. *J Org Chem.* 2011; 76:3166–3173. [PubMed: 21452877]
48. Spencer RK, Li H, Nowick JS. X-ray crystallographic structures of trimers and higher-order oligomeric assemblies of a peptide derived from Aβ(17–36). *J Am Chem Soc.* 2014; 136:5595–5598. [PubMed: 24669800]
49. Bergfors T. Seeds to crystals. *J Struct Biol.* 2003; 142:66–76. [PubMed: 12718920]
50. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: An open-source platform for biological-image analysis. *Nat Methods.* 2012; 9:676–682. [PubMed: 22743772]

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.jmb.2015.09.020>.




Fig. 1. Structure of the CdiA-CT/CdiI₀₁₁^{EC869} complex and alignments of toxin and immunity homologues. (a) Cartoon representation of the CdiA-CT/CdiI₀₁₁^{EC869} complex structure (PDB ID: 4G6U) with the toxin and immunity colored green and cyan, respectively. Toxin active-site residues are rendered in space-filling model and the Zn²⁺ ion is represented by a purple sphere. (b) Protein sequence alignment of the CdiA-CT₀₁₁^{EC869} nuclease domain and its homologues. Active-site residues are outlined in red boxes, and the β 4/ β 5-hairpin is outlined in a green box. (c) Protein sequence alignment of the CdiI₀₁₁^{EC869} immunity protein and its homologues. Residues that form H-bond or ion-pair interactions with CdiA-CT₀₁₁^{EC869} are marked with green boxes. The location of CdiI^{YPIII} elongated loop (E-L*) is indicated with a magenta bar. For (b) and (c), alignments were prepared using Jalview, with progressively darker shades of purple indicating greater residue conservation. The secondary-structure elements shown are from the CdiA-CT/CdiI₀₁₁^{EC869} complex structure.




Fig. 2. The structure of the CdiA-CT/CdiI^{YPIII} complex. (a) Ribbon representation of the CdiA-CT/CdiI^{YPIII} complex with toxin and immunity proteins colored orange and purple, respectively. Location of the CdiA-CT^{YPIII} β 4/ β 5-hairpin is indicated. (b) Structural superimposition of the β -hairpin binding regions of CdiA-CT/CdiI_{O11}^{EC869} and CdiA-CT/CdiI^{YPIII}. CdiA-CT_{O11}^{EC869} and CdiI_{O11}^{EC869} are colored green and cyan, respectively. CdiA-CT^{YPIII} residues that form a salt-bridge via loop L1 are depicted as sticks. (c) Predicted active-site residues of CdiA-CT_{O11}^{EC869} (carbons in green) and CdiA-CT^{YPIII} (carbons in orange). Residue labels correspond to both toxins. The Zn²⁺ ion was observed in the CdiA-CT_{O11}^{EC869} structure and is shown as a purple sphere. Extended loop (E-L*) of CdiI^{YPIII} is labeled in (a) and (b).




Fig. 3. Comparison of the β -augmentation interactions. (a) Ribbon representation of the CdiA-CT/CdiI₀₁₁^{EC869} complex with toxin and immunity proteins are colored green and cyan, respectively. Residues at the complex interface involved in direct ion pair or H-bond interactions are shown in stick representation, with carbon atoms colored as stated for above: oxygen and nitrogen atoms are colored red and blue, respectively. Water molecules at the interface are represented as red spheres. (b) Ribbon representation of the CdiA-CT/CdiI^{YPIII} complex with toxin and immunity proteins colored orange and purple, respectively. Residues and water molecules represented and colored as in (a).




Fig. 4. CdiA-CT^{YPIII} has DNase activity *in vitro*. Supercoiled plasmid DNA was incubated with purified CdiA-CT_{o11}^{EC869} or CdiA-CT^{YPIII} in the presence of either Mg²⁺ or Zn²⁺ and then analyzed by agarose gel electrophoresis and ethidium bromide staining. Reactions were supplemented with purified CdiI_{o11}^{EC869} or CdiI^{YPIII} immunity proteins where indicated. Untreated supercoiled plasmid substrate and linearized plasmid were included as controls for the migration of undigested DNA. The migration positions of linear molecular weight (MW) DNA standards are indicated in kilobase pairs (kb).




Fig. 5. CdiI_{o11}^{EC869} and CdiI^{YPK} confer specific immunity to CDI. (a) Competition co-cultures. Inhibitor cells that deploy CdiA-CT_{o11}^{EC869} (from pCH9305) or CdiA-CT^{YPK} (from pCH2409) were incubated at a 1:1 ratio with target cells that express CdiI_{o11}^{EC869} (from pCH9315), CdiI-^{YPK} (from pCH848) or no immunity at all (none, pTrc99a vector). Viable target cells were quantified as colony-forming units (c.f.u.) per milliliter at the beginning of the co-culture and after 4 h. Data represent the average \pm standard error of the mean for three independent experiments. (b) Fluorescence microscopy of competition co-cultures. YFP-labeled inhibitor cells were co-cultured with mKate2-labeled target strains that carry


the indicated immunity genes. Cells were stained with DAPI to visualize genomic DNA at 0 and 4 h of co-culture.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Fig. 6.**

Deletion of the CdiA-CT^{EC869} β-hairpin disrupts complex formation. (a) Ribbon representation of the CdiA-CT/CdiI^{EC869} complex interface. CdiA-CT^{EC869}, CdiI^{EC869} and the β-hairpin colored green, cyan and olive, respectively. The Gly - Ser - Gly linker in CdiA-CT^{EC869/Δβ4β5} is depicted as a red broken line. (b) His₆-tagged CdiI^{EC869} was co-expressed with CdiA-CT^{EC869} or CdiA-CT^{EC869/Δβ4β5}, followed by purification via Ni²⁺-affinity chromatography and then analysis by SDS/PAGE gel. Relevant molecular weight standards are labeled. The flow-through (FT), wash (W) and elution fractions (E) are indicated. (c) CD spectra of purified CdiA-CT^{EC869} and CdiA-CT^{EC869/Δβ4β5}.





Fig. 7. Toxin β -hairpin sequence contributes to complex binding affinity. (a) Protein sequence alignment of the β -hairpin region (boxed) of CdiA-CT₀₁₁^{EC869}, CdiA-CT^{Nlact} and CdiA-CT^{Ykris}. CdiA-CT₀₁₁^{EC869} residues that interact with CdiI₀₁₁^{EC869} are shown in green. Red residues indicate sequence differences with respect to CdiA-CT₀₁₁^{EC869}. (b) CdiI₀₁₁^{EC869}-His₆ was co-expressed with CdiA-CT₀₁₁^{EC869} containing the β -hairpins from either *N. lactamica* or *Y. kristensenii* then purified by Ni²⁺-affinity chromatography and analyzed by SDS-PAGE. The molecular mass standards are indicated in kilodaltons (kDa). The flow-through (FT) and wash fractions (W1 and W2) are indicated followed by elution with imidazole gradient. (c) CD spectra of purified CdiA-CT₀₁₁^{EC869/Nlact} and CdiA-CT₀₁₁^{EC869/Ykris} show similar secondary-structure content compared to wild-type CdiA-CT₀₁₁^{EC869}.

**Fig. 8.**

Structure of the MAC- CdiI^{EC869}₀₁₁ complex. (a) Crystal structure with CdiI^{EC869}₀₁₁ depicted as orange ribbons and MAC displayed as sticks, carbon, nitrogen, oxygen and ornithine carbons colored magenta, blue, red and pink, respectively. The MAC $2F_o - F_c$ electron density map is shown in a gray mesh and contoured at 1.0σ . (b) Structural superimposition of MAC [colored same as (a)] and the CdiA- CT/CdiI^{EC869}₀₁₁ complex. Only residues Lys242–Ser253 of the CdiA- CT/CdiI^{EC869}₀₁₁ β-hairpin are shown (green). CdiI^{EC869}₀₁₁ is colored teal and helix α3* is labeled. (c) MAC interacts with CdiI^{EC869}₀₁₁ through a network of H-bonds and ion pairs. Interacting bonds are shown as black dotted lines. CdiI^{EC869}₀₁₁ β-strands that H-bond with MAC (β3* and β7*) are shown as sticks. (d) Surface representation of the CdiI^{CT-MAC} structure, oriented as in (a) and (b), depicting the complementarity of MAC and CdiI^{EC869}₀₁₁.

Table 1

X-ray diffraction data and atomic refinement.

	CdiA-CT/CdiI ^{YPIII}	CdiI ^{Ykris}	MAC/CdiI ₀₁₁ ^{EC869}
Space group	<i>C</i> 2	<i>P</i> 3 ₁	<i>P</i> 2 ₁
Unit cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	65.5, 65.5, 71.5	54.4, 54.4, 54.4	34.8, 128.2, 45.0
β (°)	92.18		112.73
pH of crystallization condition	7.0	7.4	6.0
Protein concentration (mg/mL)	10	12.5	7.5
<i>Dataset</i>			
Wavelength (Å)	1.0	1.0	1.0
Resolution range	46.49–2.1	50.0–1.8	50.0–2.0
Unique reflections (total)	18,152	16,618	23,561
Completeness (%) ^a	99.4 (98.3)	99.7 (100)	96.5 (92.1)
Redundancy ^a	3.5 (3.5)	5.4 (5.5)	3.1 (3.1)
<i>R</i> _{merge} ^{a,b}	0.059 (0.460)	0.161 (0.607)	0.076 (0.485)
<i>I</i> /σ(<i>I</i>) ^a	10.0 (1.6)	9.48 (3.1)	11.1 (3.1)
NCS copies	1	1	2
Other ions	2 Cl ⁻	—	2 Cl ⁻
<i>Model refinement</i>			
Resolution range (Å)	46.49–2.09	23.58–1.80	34.81–2.00
No. of reflections (working/free)	18,149/1851	16,580 (1673)	23,526 (2004)
No. of protein atoms	2308	1283	2596
No. of water molecules	148	130	132
No. of CT-MAC atoms	—	—	222
Missing residues	1–173, 298 (CdiA) 1–2 (CdiI)	None	1, 168, 169
<i>R</i> _{work} / <i>R</i> _{free} ^c (%)	20.5/25.6	18.1/22.1	18.4/23.1
rmsd			
Bond lengths (Å)	0.003	0.007	0.009
Bond angles (°)	0.694	0.998	1.222
Ramachandran plot			
Most favorable region (%)	95.25	98.77	97.13
Additional allowed region (%)	4.75	1.23	2.87
Disallowed region	0	0	0
PDB code	4ZQU	4ZQV	4ZQW

*R*_{free} was computed identically except where all reflections belong to a test set of 10% randomly selected data.

^a Statistics for the highest-resolution shell are given in brackets.

^b $R_{\text{merge}} = \sum |I - \langle I \rangle| / \sum \langle I \rangle$.

^c $R_{\text{work}} = \sum |F_{\text{O}} - F_{\text{C}}| / \sum F_{\text{O}}$.

Table 2Dissociation constants (μM) of CdiA-CT and CdiI interactions determined using biolayer interferometry.

	CdiA- CT _{o11} ^{EC869}	CdiA- CT _{o11} ^{EC869/Ykris}	CdiA- CT _{o11} ^{EC869/Nlact}
CdiI_{o11}^{EC869}	0.018 \pm 0.007	46 \pm 36	0.18 \pm 0.10
CdiI^{Ykris}	5.0 \pm 0.4	24 \pm 14	5.8 \pm 3
CdiI^{Nlact}	82 \pm 18	3.2 \pm 2	0.17 \pm 0.09

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript